<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>The Nevada National Board Professional Learning Institute | Fallon | Activity</title>
	<link>http://www.nationalboardinstitute.com/members/alarmrussia70/activity/</link>
	<atom:link href="http://www.nationalboardinstitute.com/members/alarmrussia70/activity/feed/" rel="self" type="application/rss+xml" />
	<description>Activity feed for Fallon.</description>
	<lastBuildDate>Fri, 23 May 2025 17:06:54 -0700</lastBuildDate>
	<generator>https://buddypress.org/?v=9.1.1</generator>
	<language>en-US</language>
	<ttl>30</ttl>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>2</sy:updateFrequency>
	
						<item>
				<guid isPermaLink="false">9557b0abcecadd8ce2e07696bc61c0ba</guid>
				<title>Fallon posted an update: There were no anaphylactic reactions. All infusion reactions [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/40757/</link>
				<pubDate>Fri, 07 Feb 2025 09:07:17 -0800</pubDate>

									<content:encoded><![CDATA[<p>There were no anaphylactic reactions. All infusion reactions occurred within 4 hours of starting IVIG. No hypotension reactions occurred after 4 hours. All subjects were able to complete their IVIG infusion without any further complications. CONCLUSIONS Given that the maximum IVIG infusion rate is reached at 1.5 hours per our hospital&#8217;s policy and&hellip;<span class="activity-read-more" id="activity-read-more-40757"><a href="http://www.nationalboardinstitute.com/activity/p/40757/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">73ece717832690bb833b52c7f102706c</guid>
				<title>Fallon posted an update: 8 years. Day 100 transplant-related mortality (TRM) was 0%. [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/36239/</link>
				<pubDate>Sun, 02 Feb 2025 09:11:59 -0800</pubDate>

									<content:encoded><![CDATA[<p>8 years. Day 100 transplant-related mortality (TRM) was 0%. <a href="https://www.selleckchem.com/products/picropodophyllin-ppp.html" rel="nofollow ugc">check details</a> Two patients died at later time points, 1 from intracranial hemorrhage/disseminated fungal infection in the setting of graft failure and 1 from infection/GVHD. The estimated probabilities of grades II-IV and III-IV acute GVHD at day 100 and 2-year NIH-consensus chronic GVHD&hellip;<span class="activity-read-more" id="activity-read-more-36239"><a href="http://www.nationalboardinstitute.com/activity/p/36239/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">550f270ba1f0872b4b95359145b2151f</guid>
				<title>Fallon posted an update: Present work revealed promising outcomes of modifying [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/34493/</link>
				<pubDate>Fri, 31 Jan 2025 09:12:51 -0800</pubDate>

									<content:encoded><![CDATA[<p>Present work revealed promising outcomes of modifying strategies. However, it also revealed a need for field-based evidence mainly regarding epidemiologic and long-term impact. It pointed out some eventual irreversible and important effects that must not be ignored when considering open-field releases, and that may constitute constraints to&hellip;<span class="activity-read-more" id="activity-read-more-34493"><a href="http://www.nationalboardinstitute.com/activity/p/34493/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">b597a9e54602ac8feb1a636686c6ca83</guid>
				<title>Fallon posted an update: Purpose With the initiation of human hyperpolarized 13 C [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/33391/</link>
				<pubDate>Thu, 30 Jan 2025 09:06:47 -0800</pubDate>

									<content:encoded><![CDATA[<p>Purpose With the initiation of human hyperpolarized 13 C (HP-13 C) trials at multiple sites and the development of improved acquisition methods, there is an imminent need to maximally extract diagnostic information to facilitate clinical interpretation. This study aims to improve human HP-13 C MR spectroscopic imaging through means of Tensor Rank&hellip;<span class="activity-read-more" id="activity-read-more-33391"><a href="http://www.nationalboardinstitute.com/activity/p/33391/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">d04a09cc224c77b35b4cec705d5d55e7</guid>
				<title>Fallon posted an update: Chronic spontaneous urticaria (CSU) is defined as the [&#133;]</title>
				<link>http://www.nationalboardinstitute.com/activity/p/26817/</link>
				<pubDate>Tue, 28 Jan 2025 08:29:00 -0800</pubDate>

									<content:encoded><![CDATA[<p>Chronic spontaneous urticaria (CSU) is defined as the spontaneous development of itchy hives and/or angioedema due to known or unknown causes that last for at least 6 weeks. At any given time, CSU is believed to affect 0.5-1% of the global population. Omalizumab (a recombinant, humanized anti-immunoglobulin-E antibody) is the only approved&hellip;<span class="activity-read-more" id="activity-read-more-26817"><a href="http://www.nationalboardinstitute.com/activity/p/26817/" rel="nofollow ugc">[Read more]</a></span></p>
]]></content:encoded>
				
									<slash:comments>0</slash:comments>
				
							</item>
					<item>
				<guid isPermaLink="false">0d50e82bb4e1ca3fd34f9e684af8dab0</guid>
				<title>Fallon became a registered member</title>
				<link>http://www.nationalboardinstitute.com/activity/p/26749/</link>
				<pubDate>Tue, 28 Jan 2025 08:24:58 -0800</pubDate>

				
									<slash:comments>0</slash:comments>
				
							</item>
		
	</channel>
</rss>